Core Insights - INVO Fertility has announced a strategic partnership with Heidi Health to integrate an AI-powered scribe platform at its Wisconsin Fertility Institute, aimed at enhancing patient care and reducing administrative burdens for clinicians [1][3]. Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [5]. - The company operates two INVO Centers in the U.S. and one IVF clinic, and it is engaged in the sale and distribution of its proprietary INVOcell technology, which allows fertilization and early embryo development to occur in vivo [5]. Technology Integration - The AI-powered tool from Heidi Health automates clinical documentation, allowing clinicians to spend less time on administrative tasks, thus reducing burnout and improving patient interaction [2][3]. - The integration of the AI scribe is expected to automate over two hours of daily administrative work for clinicians, significantly decreasing manual note-taking by up to 80% [3]. Patient Experience Enhancement - The partnership aims to elevate the patient experience at the Wisconsin clinic, ensuring that individuals feel supported throughout their treatment journey [4]. - The technology will enable specialists to focus more on patient care, building trust, and personalizing treatment plans [3][4].

Core Insights - NewGen has established a joint venture with BNW to develop a strategic plot of land in Ras Al Khaimah's Beach District, UAE, marking a significant step in its diversification strategy [1][2] - The feasibility study indicates potential net returns of up to US$67 million for NewGen, representing a 272% return on investment [3][4] - NewGen will hold a 60% stake in the joint venture, while BNW will manage construction and associated costs, minimizing NewGen's initial capital requirements [1][4][5] Financial Projections - The project is expected to complete by 2028, with a projected sale price of approximately US$817 per square foot and a total saleable area of 527,753 square feet [3] - The revenue potential from this project signifies a fundamental shift in NewGen's business focus, providing substantial non-dilutive capital for further strategic expansion [4][5] Strategic Advantages - The joint venture diversifies NewGen's revenue streams and reduces dependence on a single sector, enhancing its presence in the UAE real estate market [5][6] - The project targets high-net-worth mainland Chinese buyers, leveraging NewGen's established presence in Asia and the UAE's Golden Visa Program to attract international investors [6] Partnership Dynamics - BNW, a prominent real estate developer with a portfolio valued at approximately US$6 billion, will bear all construction and management costs, allowing NewGen to focus on maximizing returns [6][9] - The partnership is seen as a strategic milestone for both companies, aiming to unlock unique asset classes with strong demand fundamentals [7][8]

Core Insights - NewGenIvf Group Limited has received a valuation report from a Big Four global accounting firm, setting the fair value of its recently acquired advanced cytometry intellectual property at US$17.9 million, which boosts the company's net asset value (NAV) per share by approximately US$8.9 [1][2] - The acquisition marks a strategic shift for NewGen from traditional IVF services to a technology-driven model, aiming to generate high-margin, recurring revenue through licensing and supplying proprietary consumables [2][4] - NewGen is pursuing regulatory approvals to commercialize the technology and plans to establish an in-house R&D team to maintain its competitive edge in the growing fertility services market, particularly in the Asia Pacific region [3][4] Company Strategy - The acquisition of advanced cytometry technology positions NewGen as a technology leader in the fertility services industry, allowing it to provide exclusive, technology-backed solutions to partner clinics without requiring upfront investments [2][4] - The company aims to create a sustainable growth model through royalty-based revenue streams, enhancing its operational capabilities and unlocking immediate value for shareholders [4] Market Context - The global fertility services market is experiencing significant growth, with 1 in 6 couples worldwide affected by infertility, presenting a substantial opportunity for NewGen to capture market share [3]

SARASOTA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tu ...

Financial Data and Key Metrics Changes - Q3 consolidated revenues increased by 5.7% year over year, reaching $1,060 million, with organic growth of 2% [5][25] - Non-GAAP earnings per share (EPS) grew by 15% year over year to $1.1, with free cash flow reported at $165 million [5][28] - Gross margin improved by 70 basis points to 67.3%, driven by efficiency gains and favorable foreign exchange [25] Business Line Data and Key Metrics Changes - CooperVision reported revenues of $718 million, reflecting a 6.3% increase and 2.4% organic growth, although results were below expectations due to declines in Clarity orders [6][9] - CooperSurgical posted revenues of $342 million, up 4.5% year over year, with fertility revenues growing 6% [20][21] - MyDay lenses showed double-digit growth, with MyDay Multifocal growing 20% [11][13] Market Data and Key Metrics Changes - EMEA region grew 14% or 6% organically, becoming CooperVision's largest revenue region globally [9] - The Americas grew 2% or 3% organically, while Asia Pac grew 1% but declined 5% organically due to Clarity pressure [9][10] - The overall contact lens market is expected to continue mid-single-digit growth, driven by a shift towards silicone hydrogel lenses [19] Company Strategy and Development Direction - The company aims to leverage strong MyDay momentum and upcoming product launches to gain market share [23][30] - Focus on operational excellence and disciplined cost management to support sustainable revenue growth [5][28] - Ongoing restructuring efforts to enhance efficiency and leverage IT upgrades [73][74] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the contact lens market, particularly in Asia Pac, but remains optimistic about long-term growth in fertility and contact lenses [20][50] - Guidance for Q4 indicates expected organic growth of 2% to 4% for both CooperVision and CooperSurgical, factoring in potential headwinds [22][23] - Confidence in achieving $2 billion in free cash flow over the next three fiscal years, supported by improved operating margins [30][102] Other Important Information - The company repurchased $52 million worth of stock during the quarter, with approximately $164 million remaining under the repurchase plan [28] - Tariff impacts are expected to be lower than previously anticipated, with mitigation strategies in place [29][30] Q&A Session Summary Question: How does the core CVI portfolio compare to market growth for fiscal 2026? - Management indicated that the core portfolio has lagged the market but expects to be at least in line with market growth, with additional contributions from MySight [36][40] Question: Why is MyDay's success impacting Clarity? - Management noted that in some markets, Clarity and MyDay were viewed similarly, leading to a shift in orders towards MyDay [41][45] Question: What is the outlook for the contact lens market's growth? - Management acknowledged a slowdown in market growth but remains confident in the long-term fundamentals, including pricing and consumer trends [50][52] Question: What are the drivers for expected Q4 rebound in fertility? - Management highlighted improvements in genomics and consumables, along with anticipated investments from fertility clinics [110][114] Question: What is the situation with PARAGARD and market dynamics? - Management confirmed no new competitive launches but acknowledged declining volumes, offset by pricing strategies [117][119]

Core Viewpoint - INVO Fertility, Inc. reported its second quarter 2025 financial results, highlighting a focus on expanding fertility operations and innovative service offerings while navigating a net loss from continuing operations. Financial Highlights - Revenue for Q2 2025 was $1,863,654, marking a 1% increase from $1,836,597 in Q2 2024, setting a new quarterly record for the company [7] - Consolidated clinic revenue increased by 1% to $1,832,094 compared to $1,807,921 in the previous year [7] - Total revenue from all clinics, including consolidated and equity method clinics, rose by 2% to $2,188,893 from $2,141,229 [7] - Net loss from continuing operations was $(3.2) million, compared to $(2.2) million in the prior year [7] - Adjusted EBITDA was $(587,230), a decline from $(509,623) in Q2 2024 [7][15] Operational Highlights - The company completed the divestiture of a majority stake in NAYA on June 2, 2025, allowing both INVO Fertility and NAYA to focus on their respective operations [4] - INVO Fertility expanded its service offerings to include telehealth options and Platelet-Rich Plasma (PRP) therapy at its Wisconsin clinic, enhancing patient-centered care [5][7] - The Wisconsin Fertility Institute was recognized on Newsweek's List of America's Best Fertility Clinics for 2025 [7] - A new patent for a modified version of the INVOcell device was allowed, extending intellectual property protection through 2040 [7] Management Commentary - The CEO emphasized the commitment to growth and innovation in fertility operations, highlighting the expansion of services and training support for INVOcell technology [5] - The company aims to maintain an efficient and scalable operating structure while integrating complementary revenue-generating businesses and technologies [5]

Core Insights - NewGen has acquired advanced cytometry technology and assets, including 18 fully-constructed cell-sorting systems and six related patents, to enhance its market position and support U.S. expansion [1][2][4] - The U.S. fertility services market is growing, with over 432,000 IVF cycles performed in 2023, indicating a significant opportunity for NewGen's NewGenSort services [3][5] Company Developments - The acquisition builds on NewGen's earlier purchase of MicroSort technology, now rebranded as NewGenSort, which allows for precise separation of sperm cells based on chromosomal content [2][5] - NewGen anticipates that its U.S. operations could generate over $20 million in annual gross revenue once fully operational, based on conservative pricing and utilization assumptions [4] Market Context - The Society for Assisted Reproductive Technology reported an increase in IVF cycles from 389,993 in 2022 to 432,641 in 2023, with IVF births rising from 91,771 to 95,860 during the same period [3] - Each sorting system is projected to perform around four sorts per day, allowing NewGen to process over 25,000 sorts annually, which represents less than 6% of total U.S. IVF cycles [3][4] Strategic Vision - The CEO of NewGen emphasized that this acquisition is a significant milestone in the company's expansion strategy, aimed at meeting the growing demand for advanced fertility services in the U.S. market [5]

Core Viewpoint - NewGenDigital has entered into a Memorandum of Understanding with BNW Real Estate Development LLC to develop a strategic plot of land in Ras Al Khaimah, UAE, with an estimated potential net return of up to US$67 million from the project [1][4]. Group 1: Partnership Details - The MOU aims to negotiate a Joint Venture Agreement to form a special-purpose vehicle for the development of the plot [1]. - BNW is responsible for all construction and management costs, while NewGenDigital will contribute 36% of the land cost, estimated at about US$24 million [3]. - BNW will initially cover the remaining 64% of the land cost and any payments made on behalf of NewGenDigital will be deducted from its final entitlement [3]. Group 2: Financial Projections - A feasibility study by BNW estimates a net return of up to US$67 million for NewGenDigital, representing a 272% return on investment after accounting for costs [4]. - The projected sale price is estimated at AED3,000 per square foot (approximately US$817), with a total saleable area of 527,753 square feet [4]. - Consultant, construction, and administration costs are estimated at AED823 per square foot [4]. Group 3: Company Background - NewGen is a comprehensive fertility services provider in Asia, with clinics in Thailand, Cambodia, and Kyrgyzstan, offering a full suite of fertility treatments [6]. - The company aims to expand beyond its core fertility services through strategic partnerships like the one with BNW [5].

Core Viewpoint - INVO Fertility, Inc. announced a 1-for-3 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective July 21, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 3 shares of common stock into 1 share, rounding up any fractional shares [2]. - Post-split, the company will have approximately 928,272 shares issued and outstanding, with authorized shares adjusted to 1,388,888 [2]. Group 2: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell medical device [4]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and cost-effective alternative to traditional IVF [4].

Core Insights - INVO Fertility, Inc. is enhancing its fertility services through expanded clinical and embryology training support and improved pricing for its INVOcell technology, aiming to provide patient-centered care while expanding clinic operations [1][3][4] Company Overview - INVO Fertility focuses on the fertility market, operating two INVO Centers and one IVF clinic in the U.S., and aims to build, acquire, and operate more fertility clinics [6] - The company offers the INVOcell, the first FDA-cleared intravaginal culture system, which allows fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [2][6] Product and Technology - INVOcell delivers comparable pregnancy rates to conventional IVF while offering a more intimate and affordable experience for patients [2][8] - The company has secured a notice of allowance for a new patent from the U.S. Patent and Trademark Office, reinforcing its position as a technology innovator [4] Training and Support - INVO Fertility provides hands-on training and clinical support for embryologists and physicians to integrate the INVOcell solution into their practices [3] - The company is launching targeted educational campaigns to raise awareness of patient success rates with INVOcell, which are similar to those of conventional IVF [3] Market Positioning - INVOcell is positioned as an inclusive option for diverse family structures, including same-sex couples and single parents, and offers a streamlined lab workflow for clinics [8]